Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses [FOX News]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: FOX News
Monday's sweeping autism announcements have sparked deeper conversations about the widespread neurological disorder. Health officials spoke during a press conference in Washington, D.C., about possible causes, vaccine guidance and the potential for a cancer drug to double as an autism therapy. Autism diagnoses have been steadily rising in recent decades, according to the Centers for Disease Control and Prevention. "In the 1970s, autism was considered rare, perhaps 1 in 5,000 to 10,000 children," Steven Quay, M.D., Ph.D., a physician-scientist and founder of Atossa Therapeutics in Seattle, Washington, told Fox News Digital. In the year 2000, an estimated one in 150 children aged 8 had the disorder. By 2010, that number had risen to one in 68 — and by 2022, one in 31 children were diagnosed. "Autism is no longer an uncommon condition tucked away in psychiatric textbooks," said Quay. "It is part of the daily fabric of schools, clinics and families everywhere." Dr. Aggie Papa
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer ContinuumPR Newswire
- Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for GlioblastomaPR Newswire
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]Yahoo! Finance
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific PresentationPR Newswire
- Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
ATOS
Analyst Actions
- 9/22/25 - Ascendiant Capital
ATOS
Sec Filings
- 12/4/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- ATOS's page on the SEC website